Skip to main content

Table 1 Baseline demographic and disease characteristics for patients < 65 years and ≥ 65 years

From: Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age

  Patients < 65 years Patients ≥ 65 years
Placebo + MTX Golimumab + MTX Combined Placebo + MTX Golimumab + MTX Combined
Patients, n 179 336 515 18 59 77
Age, years 49.5 ± 9.9 48.7 ± 10.7 49.0 ± 10.4 70.4 ± 3.4 70.1 ± 4.3 70.2 ± 4.1
Female 141 (78.8) 276 (82.1) 417 (81.0) 16 (88.9) 50 (84.7) 66 (85.7)
Race
 Caucasian 145 (81.0) 272 (81.2) 417 (81.1) 15 (83.3) 43 (72.9) 58 (75.3)
 Asian 10 (5.6) 30 (9.0) 40 (7.8) 2 (11.1) 1 (1.7) 3 (3.9)
 Black 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.7) 1 (1.3)
 Other 24 (13.4) 33 (9.8) 57 (11.1) 1 (5.6) 14 (23.7) 15 (19.5)
Weight, kg 71.7 ± 17.4 72.4 ± 16.2 72.2 ± 16.6 73.8 ± 15.3 66.3 ± 14.3 68.1 ± 14.7
BMI, kg/m2 26.9 ± 5.7 27.0 ± 5.6 27.0 ± 5.6 28.3 ± 5.5 25.8 ± 4.9 26.4 ± 5.1
RA disease duration 6.6 ± 6.3 6.5 ± 6.3 6.5 ± 6.3 10.8 ± 13.1 9.3 ± 9.8 9.7 ± 10.6
ACR core components
 Number of swollen joints (0–68) 14.7 ± 8.4 15.0 ± 8.5 14.9 ± 8.5 15.9 ± 9.8 14.6 ± 6.2 14.9 ± 7.2
 Numbers of tender joints (0–68) 25.9 ± 14.3 26.6 ± 13.7 26.3 ± 13.9 25.8 ± 12.8 25.5 ± 15.2 25.6 ± 14.6
 CRP, mg/dL 2.3 ± 1.9 2.8 ± 2.7 2.6 ± 2.5 1.5 ± 1.1 3.1 ± 3.7 2.7 ± 3.4
 Physician’s global assessment (VAS, 0–10 cm) 6.3 ± 1.5 6.3 ± 1.6 6.3 ± 1.6 5.9 ± 2.0 6.0 ± 1.7 5.9 ± 1.7
 Patient’s global assessment (VAS, 0–10 cm) 6.5 ± 1.9 6.5 ± 1.8 6.5 ± 1.9 6.2 ± 2.2 6.3 ± 1.8 6.3 ± 1.9
 Patient’s assessment of pain (VAS, 0–10 cm) 6.5 ± 2.0 6.5 ± 1.9 6.5 ± 1.9 6.6 ± 2.0 6.5 ± 1.6 6.5 ± 1.7
 HAQ-DI 1.60 ± 0.60 1.55 ± 0.66 1.56 ± 0.64 1.35 ± 0.72 1.61 ± 0.71 1.55 ± 0.72
 Anti-CCP antibodies 165/177 (93.2) 307/335 (91.6) 472/512 (92.2) 16 (88.9) 55 (93.2) 71 (92.2)
 Rheumatoid factor 164 (91.6) 309 (92.0) 473 (91.8) 17 (94.4) 56 (94.9) 73 (94.8)
 SF-36 PCS 30.8 ± 7.2 31.0 ± 6.6 30.9 ± 6.8 31.7 ± 8.9 30.0 ± 7.8 30.4 ± 8.0
 SF-36 MCS 38.3 ± 11.7 36.8 ± 11.1 37.3 ± 11.3 41.0 ± 10.4 38.9 ± 11.1 39.4 ± 10.9
Concomitant medications
 MTX dose at screening 16.7 ± 2.8 16.9 ± 2.9 16.8 ± 2.9 16.4 ± 2.9 16.3 ± 2.8 16.3 ± 2.8
  Duration of MTX use
   < 1 year 44 (24.6) 82 (24.4) 126 (24.5) 4 (22.2) 20 (33.9) 24 (31.2)
   1 to < 3 years 53 (29.6) 97 (28.9) 150 (29.1) 8 (44.4) 17 (28.8) 25 (32.5)
   ≥ 3 years 82 (45.8) 154 (45.8) 236 (45.8) 6 (33.3) 22 (37.3) 28 (36.4)
   Unknown 0 (0.0) 3 (0.9) 3 (0.6) 0 (0.0) 0 (0.0) 0 (0.0)
 Oral corticosteroids 121 (67.6) 221 (65.8) 342 (66.4) 13 (72.2) 30 (50.8) 43 (55.8)
 Dose (prednisone or equivalent), mg/day 7.0 ± 2.5 7.1 ± 2.5 7.0 ± 2.5 6.9 ± 2.7 6.6 ± 2.7 6.7 ± 2.6
 NSAIDs 145 (81.0) 280 (83.3) 425 (82.5) 11 (61.1) 43 (72.9) 54 (70.1)
Prior medications
 DMARDs* 83 (46.4) 182 (54.2) 265 (51.5) 9 (50.0) 24 (40.7) 33 (42.9)
  1. Data presented as n (%) or mean ± standard deviation, unless otherwise noted
  2. ACR American College of Rheumatology, BMI body mass index, CCP cyclic citrullinated peptide, CRP C-reactive protein, DMARDs disease-modifying anti-rheumatic drugs, HAQ-DI health assessment questionnaire-disability index, MTX methotrexate, NSAIDs nonsteroidal anti-inflammatory drugs, RA rheumatoid arthritis, SF-36 PCS/MCS 36-item Short Form Health Survey Physical/Mental Component Summary, VAS visual analog scale
  3. *DMARDs other than MTX were discontinued ≥ 4 weeks prior to the first study agent administration